The company has had its ups -- the approval of its respiratory syncytial virus (RSV) vaccine back in 2024 -- and its downs -- the failure of its cytomegalovirus (CMV) vaccine candidate in a phase 3 ...
Deep value investor Lee Roach is looking at beaten-down software stocks for the first time ever.
Traders are betting investments in the technology won’t pay off as investors become increasingly nervous about AI’s potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results